BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 32624693)

  • 1. The prediction value of PI-RADS v2 score in high-grade Prostate Cancer: a multicenter retrospective study.
    Chen S; Yang Y; Peng T; Yu X; Deng H; Guo Z
    Int J Med Sci; 2020; 17(10):1366-1374. PubMed ID: 32624693
    [No Abstract]   [Full Text] [Related]  

  • 2. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
    Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
    [No Abstract]   [Full Text] [Related]  

  • 3. Exploration of the diagnostic capacity of PSAMR combined with PI-RADS scoring for clinically significant prostate cancer and establishment and validation of the Nomogram prediction model.
    Li D; Zhang L; Xu Y; Wu X; Hua S; Jiang Y; Huang Q; Gao Y
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11309-11317. PubMed ID: 37365430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
    Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
    BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and external validation of a novel nomogram to predict prostate cancer in biopsy-naïve patients with PSA <10 ng/ml and PI-RADS v2.1 = 3 lesions.
    Hu C; Sun J; Xu Z; Zhang Z; Zhou Q; Xu J; Chen H; Wang C; Ouyang J
    Cancer Med; 2023 Feb; 12(3):2560-2571. PubMed ID: 35920264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
    Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
    Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.
    Liu Y; Wang S; Xiang LH; Xu G; Dong L; Sun Y; Ye B; Zhang Y; Xu H
    Br J Radiol; 2022 Sep; 95(1138):20220209. PubMed ID: 35877385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer.
    Zhai L; Fan Y; Sun S; Wang H; Meng Y; Hu S; Wang X; Yu W; Jin J
    Scand J Urol; 2018; 52(5-6):333-339. PubMed ID: 30895901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing a new PI-RADS v2-based nomogram for forecasting high-grade prostate cancer.
    Niu XK; He WF; Zhang Y; Das SK; Li J; Xiong Y; Wang YH
    Clin Radiol; 2017 Jun; 72(6):458-464. PubMed ID: 28069159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of prostate imaging reporting and data system version 2 (PI-RADS v2) and periprostatic fat thickness on multi-parametric MRI to predict the presence of prostate cancer.
    Cao Y; Cao M; Chen Y; Yu W; Fan Y; Liu Q; Gao G; Zhao Z; Wang X; Jin J
    Oncotarget; 2017 Jul; 8(27):44040-44049. PubMed ID: 28476042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Developing a Chinese PI-RADS v2-based nomogram for predicting clinically significant prostate cancer in patients with a prior negative biopsy].
    Huang C; Song G; Wang H; Ji GJ; Chen YK; He Q; Zhou LQ
    Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2559-2563. PubMed ID: 30220139
    [No Abstract]   [Full Text] [Related]  

  • 12. A nomogram based on PI-RADS v2.1 and clinical indicators for predicting clinically significant prostate cancer in the transition zone.
    Wei C; Pan P; Chen T; Zhang Y; Dai G; Tu J; Jiang Z; Zhao W; Shen J
    Transl Androl Urol; 2021 Jun; 10(6):2435-2446. PubMed ID: 34295730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
    Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
    Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low PI-RADS assessment category excludes extraprostatic extension (≥pT3a) of prostate cancer: a histology-validated study including 301 operated patients.
    Alessi S; Pricolo P; Summers P; Femia M; Tagliabue E; Renne G; Bianchi R; Musi G; De Cobelli O; Jereczek-Fossa BA; Bellomi M; Petralia G
    Eur Radiol; 2019 Oct; 29(10):5478-5487. PubMed ID: 30887199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of prostate PI-RADS V2.1 score combined with serum PSA-related indicators in the detection of gray zone prostate cancer.
    Lin S; Yu X; Chen H; Chen Z; Yang Y
    Int Urol Nephrol; 2023 Nov; 55(11):2685-2693. PubMed ID: 37523077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the detection rate of prostate cancer in the gray zone of PI-RADS v2 and serum tPSA by using prostate-specific antigen-age volume.
    Lu YF; Zhang Q; Chen HY; Chen JY; Pan Y; Xu CC; Xu JX; Yu RS
    Medicine (Baltimore); 2019 Jun; 98(26):e16289. PubMed ID: 31261602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate imaging-reporting and data system version 2 in combination with clinical parameters for prostate cancer detection: a single center experience.
    Wang L; Luo Y; Liu T; Deng M; Huang X
    Int Urol Nephrol; 2023 Jul; 55(7):1659-1664. PubMed ID: 37171702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are prostate biopsies necessary for all patients 75years and older?
    Chen Y; Fan Y; Yang Y; Jin J; Zhou L; He Z; Zhao Z; He Q; Wang X; Yu W; Wu S
    J Geriatr Oncol; 2018 Mar; 9(2):124-129. PubMed ID: 28939384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
    J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An integrated nomogram combining deep learning, Prostate Imaging-Reporting and Data System (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study.
    Hiremath A; Shiradkar R; Fu P; Mahran A; Rastinehad AR; Tewari A; Tirumani SH; Purysko A; Ponsky L; Madabhushi A
    Lancet Digit Health; 2021 Jul; 3(7):e445-e454. PubMed ID: 34167765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.